Core Viewpoint - Evommune, a biotechnology company focused on developing therapies for chronic inflammatory diseases, has filed for an IPO to raise up to $100 million [1][2] Company Overview - Evommune is headquartered in Palo Alto, California, and was founded in 2020 [2] - The company reported revenue of $3 million for the 12 months ending June 30, 2025 [2] - The company plans to list on the New York Stock Exchange under the ticker symbol EVMN [2] Product Pipeline - The core candidate drug, EVO756, is a potent and selective oral small molecule MRGPRX2 antagonist aimed at treating chronic spontaneous urticaria (CSU) and atopic dermatitis (AD) [1] - Another investigational drug, EV0301, is a long-acting fusion protein designed for the treatment of atopic dermatitis (AD) and ulcerative colitis (UC) [1] - Evommune has initiated a Phase 2b clinical trial for EVO756, with results expected in the second half of 2026 [1] - The company plans to start a Phase 2 clinical trial for moderate to severe ulcerative colitis (UC) patients in 2026 [1] IPO Details - The IPO application was submitted to the SEC on Thursday, with plans to raise up to $100 million [1] - The joint book-running managers for the offering include Morgan Stanley, Leerink Partners, Evercore ISI, and Cantor Fitzgerald [2] - The pricing terms for the offering have not yet been disclosed [2]